StockUK listing UK0ABRLSEHealthcareQuality Compounder

H. Lundbeck A/S(0ABR) Stock Analysis | Healthcare

DKK --+0.00%
Reward69High
Risk18Low
75%Data
Strong 16% profit margin
DKK —+0.00 (+0.00%) Previous close · LSE
Market cap 65.99Bn
Reward Ratingⓘ69 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ18 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0ABR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is H. Lundbeck A/S?

Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

AI Brief Pro

The brief on H. Lundbeck A/S

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is H. Lundbeck A/S?

Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 65.99B, and a P/E ratio of 25.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (69)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

All Healthcare stocks →
Company Information
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio25.416
Beta0.191
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.